ANTIBIOTIC SENSITIVITY;
ANTIMICROBIAL ACTIVITY;
ARTICLE;
DNA SUPERCOILING;
DRUG POTENCY;
ENZYME INHIBITION;
IC 50;
NONHUMAN;
PSEUDOMONAS AERUGINOSA;
ANTI-INFECTIVE AGENTS;
CIPROFLOXACIN;
DIOXOLANES;
DNA GYRASE;
DNA TOPOISOMERASE IV;
DNA TOPOISOMERASES, TYPE II, BACTERIAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FLUOROQUINOLONES;
OFLOXACIN;
PIPERAZINES;
PRODRUGS;
PSEUDOMONAS AERUGINOSA;
QUINOLONES;
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone
YOSHIDA, T. & S. MITSUHASHI: Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. 37: 793-800, 1993
DNA gyrase: An enzyme that introduces superhelical turns into DNA
GELLERT, M. & K. MIZUUCHI, M. H. O'DEA, et al.: DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73: 3872-3876, 1976
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
FERRERO, L.; B. CAMERON, B. MANSE, et al.: Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13: 641-653, 1994
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
STOVER, C. K.; X.-Q. T. PHAM, A. L. ERWIN, et al.: Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406: 959-964, 2000
Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV
AKASAKA, T.; Y. ONODERA, M. TANAKA, et al.: Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob. Agents Chemother. 43: 530-536, 1999
Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa
NAKANO, M.; T. DEGUCHI, T. KAWAMURA, et al.: Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41: 2289-2291, 1997
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance
AKASAKA, T.; M. TANAKA, A. YAMAGUCHI, et al.: Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45: 2263-2268, 2001